SARS CoV 2 News and Research

RSS

SARS-CoV-2 vaccines modeled on South African variant may offer broad protection against other variants

Researchers in South Africa have submitted evidence that suggests that vaccines modeled on the South African variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) would not only be effective on that strain but would also function well against other variants.

8 Mar 2021

Continued vigilance needed as COVID lockdown is relaxed in England, warn researchers

Researchers have reported findings from round nine of the REal-time Assessment of Community Transmission Study (REACT-1) that estimates community prevalence of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in England.

8 Mar 2021

Sniffer dogs could be used to detect SARS-CoV-2 infections, say researchers

Researchers in Germany suggest that sniffer dogs should be considered as an additional screening tool for detecting infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

8 Mar 2021

Researchers identify new biomarkers associated with severity of COVID-19

A team of researchers from the CHUM Research Centre has identified new biomarkers associated with the severity of COVID-19 in infected patients.

8 Mar 2021

Narrowing down on small molecular inhibitors of SARS-CoV-2 key protease

A recent methodological study by researchers from the University of Luxembourg shows that the combination of virtual screening approaches, molecular dynamics simulations and machine learning can substantially facilitate small molecule screening investigations targeted at key SARS-CoV-2 viral proteins.

8 Mar 2021

New academic spin-out based in Finland introduces a nasal spray vaccine against COVID

Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID.

8 Mar 2021

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.

8 Mar 2021

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

8 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Impairments in immune response contribute to severe COVID-19

New research by a team of scientists at University Hospital RWTH Aachen in Germany and Erasmus Medical Centre in The Netherlands characterized changes in CD8+ T cells in response to SARS-CoV-2.

8 Mar 2021

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

A new paper in the journal Life presents an early review of the viral factors involved in initiating and effecting apoptosis within infected cells.

8 Mar 2021

Biden’s criticism of Trump team’s vaccine contracts is a stretch

During a March 2 news conference on the covid-19 pandemic, President Joe Biden claimed that former President Donald Trump's administration did not ensure there would be enough vaccines for the American public.

8 Mar 2021

Small negative lifestyle changes during COVID-19 lockdown could accumulate, say researchers

An interesting new study by researchers in Australia, which has been published in the journal PLOS ONE, suggests that lifestyle changes due to pandemic restrictions on outdoor mobility have been small. But they warn that these may accumulate over time.

8 Mar 2021

Novel bioinformatics tool could help improve COVID-19 diagnosis

An interesting new study by researchers at the University of Liverpool, University of Bristol and Public Health England in the UK describes a novel bioinformatics tool used to detect subgenomic messenger ribonucleic acid (mRNA) sequences from the virus. This may help develop new diagnostic tools and model the transmission of the virus.

8 Mar 2021

How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection?

One of the most challenging tasks of physicians has been differentiating between persistent COVID-19 and SARS-CoV-2 reinfection. Recently, a team of researchers analyzed SARS-CoV-2 sequences from the publicly available reports on reinfection and persistence. They further characterized the markers of reinfecting sequences and studied the mutation rate in newly evolved persistent variants.

8 Mar 2021

Study confirms B.1.1.7 variant of SARS-CoV-2 is more transmissible

A new modeling study published in the journal Science estimates the B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant is 43% to 90% more transmissible than previous coronavirus variants. The variant was initially found in Southeast England last fall.

7 Mar 2021

Saliva testing has high accuracy in detecting early cases of SARS-CoV-2

New research finds saliva testing has a high sensitivity for detecting severe acute respiratory syndrome 2 (SARS-CoV-2) in both symptomatic and asymptomatic patients.

7 Mar 2021

FDA authorizes first molecular non-prescription, at-home COVID-19 test

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Cue COVID-19 Test for Home and Over The Counter (OTC) Use.

5 Mar 2021

FDA issues emergency use authorization for T-Detect COVID Test

Today, the U.S. Food and Drug Administration issued an emergency use authorization for the T-Detect COVID Test developed by Adaptive Biotechnologies.

5 Mar 2021

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

A monoclonal antibody "cocktail" developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.

5 Mar 2021

SARS CoV 2 News and Research

SARS-CoV-2 vaccines modeled on South African variant may offer broad protection against other variants

Continued vigilance needed as COVID lockdown is relaxed in England, warn researchers

Sniffer dogs could be used to detect SARS-CoV-2 infections, say researchers

Researchers identify new biomarkers associated with severity of COVID-19

Narrowing down on small molecular inhibitors of SARS-CoV-2 key protease

New academic spin-out based in Finland introduces a nasal spray vaccine against COVID

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers present fragment-based computational design of antibodies that target structured epitopes

Impairments in immune response contribute to severe COVID-19

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

Biden’s criticism of Trump team’s vaccine contracts is a stretch

Small negative lifestyle changes during COVID-19 lockdown could accumulate, say researchers

Novel bioinformatics tool could help improve COVID-19 diagnosis

How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection?

Study confirms B.1.1.7 variant of SARS-CoV-2 is more transmissible

Saliva testing has high accuracy in detecting early cases of SARS-CoV-2

FDA authorizes first molecular non-prescription, at-home COVID-19 test

FDA issues emergency use authorization for T-Detect COVID Test

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News